Core Viewpoint - Company announced the receipt of three utility model patent certificates from the National Intellectual Property Administration, which are related to its main business products [2] Group 1: Patent Acquisition - The patents include "a pressure-resistant anti-reflux infusion pipeline," "pressure display syringe," and "fixed measurement syringe," all of which are independently developed by the company [2] - The patents will take effect from the date of the authorization announcement and are expected to enhance the company's intellectual property protection system [2] Group 2: Impact on Business - The acquisition and application of these patents are not expected to have a significant impact on the company's short-term operating performance [2] - However, the patents will contribute to the establishment of a continuous innovation mechanism, helping the company maintain its technological leadership and enhance its core competitiveness [2]

Core Viewpoint - The stock price of Canar Medical Co., Ltd. closed at 24.22 yuan on August 20, 2025, reflecting a decrease of 0.14 yuan or 0.57% from the previous trading day [1] Company Overview - Canar Medical operates in the medical device sector, focusing on the research, production, and sales of medical products, veterinary products, and laboratory consumables [1] - In the 2024 annual report, medical products accounted for 51.23% of the company's revenue, while veterinary products made up 39.03% [1] Recent Developments - On August 20, 2025, Canar Medical announced that its wholly-owned subsidiary, Jiangsu Canar Medical Technology Co., Ltd., received three utility model patent certificates from the National Intellectual Property Administration. The patents include "a pressure-resistant anti-backflow infusion pipeline," "a pressure display syringe," and "a fixed measurement syringe," all of which are related to the company's main business products [1] Financial Performance - On August 20, 2025, the main funds experienced a net outflow of 716,700 yuan, with a cumulative net outflow of 4,222,500 yuan over the past five days [1]

Core Viewpoint - The company, Canar Medical Technology Co., Ltd., a wholly-owned subsidiary of Canar Co., has recently received three utility model patent certificates from the National Intellectual Property Administration of China, indicating a significant advancement in its product offerings [1] Group 1 - The patents awarded include "A Pressure-Resistant Anti-Backflow Infusion Pipeline," "Pressure Display Syringe," and "Fixed Measurement Syringe," showcasing the company's innovation in medical technology [1]